Research institution
The First Affiliated Hospital of Zhengzhou University Clinical Trials
Studies where The First Affiliated Hospital of Zhengzhou University is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 54Cancer, Circulating Tumor DNA Detection
Detection Technology of Peripheral Blood ctDNA Based on CRISPR/Cas and Gold Nanoparticles
This study tests a new, fast blood test that may help detect very small traces of tumor DNA in the bloodstream. When tumor cells die, they release small pieces of DNA called circulating tumor DNA (ctDNA) into the blood.
- Trial name
- NCT07916636
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma
This is an open-label, prospective, interventional study designed to enroll 34 patients with locally advanced gastric or gastroesophageal junction adenocarcinoma, aiming to evaluate and observe the efficacy and safety of QL1706…
- Trial name
- NCT07828873
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706), Docetaxel, Oxaliplatin
- Where
- China
- Volunteers
- 34 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Pancreatic Cancer
Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer
This is a single-arm, prospective, multicenter, open-label clinical trial, which aims to observe and evaluate the efficacy and safety of Relafen-α combined with famitinib and AG chemotherapy as first-line therapy in patients with…
- Trial name
- NCT07814859
- Testing
- Retlirafusp alfa Injection, Famitinib, AG
- Where
- China
- Volunteers
- 88 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Advanced Gastric Cancer, SHR1701
PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
Immunotherapy combined with chemotherapy has become the standard first-line treatment regimen for gastric cancer. However, a subset of patients still fail to benefit or derive only limited benefit from this approach.
- Trial name
- NCT07294664
- Testing
- SHR1701, SHR2554, CAPOX
- Where
- China
- Volunteers
- 78 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Esophageal Varices
A Prospective, Multicenter, Randomized Controlled Trial Investigating the Impact of Fasting Duration on Postoperative Rebleeding Following Esophageal Variceal Ligation.
To evaluate the efficacy and safety of early postoperative oral intake (with a fasting period of 6 hours) versus delayed postoperative oral intake (with fasting periods of 24 hours or 48 hours) in patients with cirrhosis…
- Trial name
- NCT07774143
- Testing
- fasting periods of 24 hours, fasting periods of 48 hours, fasting periods of 6 hours
- Where
- 12 sites in China
- Volunteers
- 339 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
GC/GEJC
A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer
This study is a prospective, randomized, non-controlled, open-label clinical trial aimed at evaluating the efficacy and safety of adebrelimab combined with apatinib mesylate and albumin-bound paclitaxel, as well as apatinib…
- Trial name
- NCT07770113
- Testing
- Adebrelimab, Apatinib, Albumin-bound paclitaxel
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Esophageal Squamous Cell Carcinoma
Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
This prospective, multicenter diagnostic accuracy study will develop and validate a standardized 3.0-T magnetic resonance imaging (MRI) acquisition protocol and structured reporting system for primary esophageal squamous cell…
- Trial name
- ESCC-MRI-TRG (NCT07769658)
- Testing
- Standardized 3.0-T Esophageal Magnetic Resonance Imaging
- Where
- 7 sites in China
- Volunteers
- 500 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Acute Ischemic Stroke
Pro-urokinase for Extended-Window Posterior Circulation Stroke
This study aims to evaluate whether, in patients with imaging-confirmed acute ischemic stroke of the posterior circulation presenting within 4.5-24 hours after symptom onset and not scheduled for endovascular thrombectomy…
- Trial name
- PROMISE (NCT07617870)
- Testing
- rhPro-UK, Aspirin
- Where
- China
- Volunteers
- 586 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Health Related
Newborns From Patients Treated With ART (Assisted Reproductive Technology)
The Prospective Cohort Study for Newborns from patients treated with ART was set up to investigate the short- and long-term health consequences in Reproductive Medical Center, First Affiliated Hospital of Zhengzhou University…
- Trial name
- NCT03993158
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Relapsed/Refractory Glioma
A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma
This study is a prospective, single-arm clinical trial aimed at evaluating the safety and efficacy of ivoximab combined with temozolomide in the treatment of relapsed/refractory glioma.
- Trial name
- NCT07599371
- Testing
- Ivoximab 20 mg/kg, ivgtt, Q4W, Temozolomide (TMZ)
- Where
- China
- Volunteers
- 29 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University